{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:44:30Z","timestamp":1790729070495,"version":"4.1.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["worldallergyorganizationjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Allergy Organization Journal"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.waojou.2022.100737","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T17:56:32Z","timestamp":1673891792000},"page":"100737","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Risks and safety of biologics: A practical guide for allergists"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5607-2407","authenticated-orcid":false,"given":"Andrea N.","family":"Sitek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanai","family":"Pongdee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.waojou.2022.100737_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27031075","article-title":"The pharmaceutical industry in 2021. An analysis of FDA drug approvals from the perspective of molecules","volume":"27","author":"de la Torre","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.waojou.2022.100737_bib2","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jaip.2020.10.048","article-title":"How to assess effectiveness of biologics for asthma and what steps to take when there is not benefit","volume":"9","author":"Pepper","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.waojou.2022.100737_bib3","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jaci.2011.04.010","article-title":"American Academy of Allergy, asthma & Immunology\/American College of Allergy, asthma & Immunology omalizumab-associated anaphylaxis joint task force follow-up report","volume":"128","author":"Cox","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2022.100737_bib4","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jaci.2007.09.032","article-title":"American Academy of Allergy, asthma & Immunology\/American College of Allergy, asthma and Immunology joint task force report on omalizumab-associated anaphylaxis","volume":"120","author":"Cox","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2022.100737_bib5","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.jaci.2017.07.013","article-title":"Anaphylaxis associated with omalizumab administration: risk factors and patient characteristics","volume":"140","author":"Lieberman","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2022.100737_bib6","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.jaci.2007.09.022","article-title":"Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma","volume":"120","author":"Limb","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2022.100737_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12038","article-title":"Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab","volume":"11","author":"Li","year":"2021","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.waojou.2022.100737_bib8","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaci.2014.08.025","article-title":"The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy","volume":"135","author":"Namazy","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2022.100737_bib9","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jaci.2019.05.019","article-title":"Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort","volume":"145","author":"Namazy","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2022.100737_bib10","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1513\/AnnalsATS.201806-400PP","article-title":"Implications of changes\u00a0in\u00a0U.S. Food and drug administration prescribing\u00a0information regarding the safety and use of asthma biologics during pregnancy","volume":"15","author":"Schatz","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.waojou.2022.100737_bib11","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.jaci.2012.01.033","article-title":"Omalizumab and the risk of malignancy: results from a pooled analysis","volume":"129","author":"Busse","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2022.100737_bib12","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jaci.2014.02.007","article-title":"Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab","volume":"134","author":"Long","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2022.100737_bib13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri2992","article-title":"Diversity and dialogue in immunity to helminths","volume":"11","author":"Allen","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.waojou.2022.100737_bib14","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2222.2007.02650.x","article-title":"Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection","volume":"37","author":"Cruz","year":"2007","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.waojou.2022.100737_bib15","doi-asserted-by":"crossref","first-page":"e912","DOI":"10.1093\/milmed\/usz357","article-title":"A\u00a0case of serum sickness-like reaction in an adult treated with omalizumab","volume":"185","author":"Weiss","year":"2020","journal-title":"Mil Med"},{"key":"10.1016\/j.waojou.2022.100737_bib16","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/pai.12877","article-title":"Serum sickness-like reaction in a pediatric patient using omalizumab for chronic spontaneous urticaria","volume":"29","author":"Eapen","year":"2018","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.waojou.2022.100737_bib17","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jaci.2007.06.038","article-title":"Severe serum sickness-like syndrome after omalizumab therapy for asthma","volume":"120","author":"Pilette","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2022.100737_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-240078","article-title":"Omalizumab-associated eosinophilic granulomatosis with polyangiitis: cause or coincidence?","volume":"14","author":"Carson","year":"2021","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.waojou.2022.100737_bib19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1177\/0394632015572567","article-title":"Development of eosinophilic granulomatosis with poliangiitis (Churg-Strauss syndrome) and brain tumor in a patient after more than 7 years of omalizumab use: a case report","volume":"28","author":"Borekci","year":"2015","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.waojou.2022.100737_bib20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/OARRR.S259746","article-title":"Transient eosinophilic granulomatosis with polyangiitis-like vasculitis during omalizumab therapy: a case report","volume":"12","author":"Elhadari","year":"2020","journal-title":"Open Access Rheumatol"},{"key":"10.1016\/j.waojou.2022.100737_bib21","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejim.2007.09.001","article-title":"Churg-Strauss syndrome associated with omalizumab","volume":"19","author":"Puechal","year":"2008","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.waojou.2022.100737_bib22","first-page":"515","article-title":"Churg-Strauss syndrome in a patient treated with omalizumab","volume":"23","author":"Cisneros","year":"2013","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.waojou.2022.100737_bib23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jaci.2007.10.040","article-title":"Development of Churg-Strauss syndrome with controlled asthma during omalizumab treatment","volume":"121","author":"Ruppert","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2022.100737_bib24","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.waojou.2022.100737_bib25","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.waojou.2022.100737_bib26","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.waojou.2022.100737_bib27","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.waojou.2022.100737_bib28","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.clinthera.2019.07.007","article-title":"Long-term safety and clinical benefit of mepolizumab in patients with the most severe eosinophilic asthma: the COSMEX study","volume":"41","author":"Khurana","year":"2019","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.waojou.2022.100737_bib29","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2018.09.033","article-title":"Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma","volume":"143","author":"Khatri","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.waojou.2022.100737_bib30","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.clinthera.2016.07.010","article-title":"Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study","volume":"38","author":"Lugogo","year":"2016","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.waojou.2022.100737_bib31","series-title":"The Mepolizumab Pregnancy Exposure Study Medical Affairs GlaxoSmithKline Phamaceuticals","year":"2022"},{"key":"10.1016\/j.waojou.2022.100737_bib32","series-title":"Mepolizumab [package insert]","year":"2022"},{"key":"10.1016\/j.waojou.2022.100737_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-233161","article-title":"Case of paradoxical adverse response to mepolizumab with mepolizumab-induced alopecia in severe eosinophilic asthma","volume":"13","author":"Nixon","year":"2020","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.waojou.2022.100737_bib34","doi-asserted-by":"crossref","first-page":"162","DOI":"10.5056\/jnm19175","article-title":"A\u00a0unique case of non-cardiac chest pain caused by mepolizumab: case report and review\u00a0of the literature","volume":"26","author":"Korbitz","year":"2020","journal-title":"J\u00a0Neurogastroenterol Motil"},{"key":"10.1016\/j.waojou.2022.100737_bib35","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jaip.2019.07.038","article-title":"Safety of reslizumab in uncontrolled asthma with eosinophilia: a pooled analysis from 6 trials","volume":"8","author":"Virchow","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.waojou.2022.100737_bib36","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.waojou.2022.100737_bib37","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.waojou.2022.100737_bib38","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.waojou.2022.100737_bib39","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-2600(18)30406-5","article-title":"Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial","volume":"7","author":"Busse","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.waojou.2022.100737_bib40","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.jaip.2020.11.060","article-title":"Successful pregnancy in the setting of eosinophil depletion by benralizumab","volume":"9","author":"Manetz","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.waojou.2022.100737_bib41","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/crj.12998","article-title":"Disseminated herpes zoster following treatment with benralizumab","volume":"13","author":"Mishra","year":"2019","journal-title":"Clin Res J"},{"key":"10.1016\/j.waojou.2022.100737_bib42","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.anai.2021.08.006","article-title":"Cytokine-release hypersensitivity reaction after the first dose of benralizumab for severe eosinophilic asthma","volume":"127","author":"Morgenstern-Kaplan","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.waojou.2022.100737_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-244733","article-title":"Non-infective cystitis secondary to benralizumab immunotherapy","volume":"15","author":"Murray","year":"2022","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.waojou.2022.100737_bib44","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.waojou.2022.100737_bib45","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.waojou.2022.100737_bib46","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jdermsci.2019.02.002","article-title":"Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)","volume":"94","author":"Thaci","year":"2019","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.waojou.2022.100737_bib47","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/bjd.18434","article-title":"Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)","volume":"182","author":"Wollenberg","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.waojou.2022.100737_bib48","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s12325-018-0702-4","article-title":"Liberty asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy\/safety in patients with uncontrolled, moderate-to-severe asthma","volume":"35","author":"Busse","year":"2018","journal-title":"Adv Ther"},{"key":"10.1016\/j.waojou.2022.100737_bib49","series-title":"Dupilumab [package Insert]","year":"2022"},{"key":"10.1016\/j.waojou.2022.100737_bib50","first-page":"5448","article-title":"Safety profile of Dupilumab during pregnancy: a data mining and disproportionality analysis of over 37,000 reports from the WHO individual case safety reporting database (VigiBase)","volume":"25","author":"Khamisy-Farah","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.waojou.2022.100737_bib51","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S2213-2600(21)00322-2","article-title":"Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.waojou.2022.100737_bib52","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jamadermatol.2019.3617","article-title":"Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial","volume":"156","author":"Worm","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.waojou.2022.100737_bib53","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.waojou.2022.100737_bib54","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.waojou.2022.100737_bib55","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.waojou.2022.100737_bib56","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaad.2019.02.053","article-title":"Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort","volume":"81","author":"Faiz","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.waojou.2022.100737_bib57","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","article-title":"Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study","volume":"82","author":"Deleuran","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.waojou.2022.100737_bib58","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jdcr.2020.11.012","article-title":"A\u00a0case report of uveitis secondary to dupilumab treatment for atopic dermatitis","volume":"7","author":"Ayasse","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.waojou.2022.100737_bib59","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12876-021-01803-8","article-title":"Anti-IL-4Ralpha monoclonal antibody dupilumab mimics ulcerative colitis: a case report","volume":"21","author":"Shimodaira","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.waojou.2022.100737_bib60","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/ced.14050","article-title":"Acute arthritis and arthralgia as an adverse drug reaction to dupilumab","volume":"45","author":"de Wijs","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.waojou.2022.100737_bib61","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.annder.2021.02.003","article-title":"Dupilumab-induced psoriasis and alopecia areata: case report and review of the literature","volume":"148","author":"Beaziz","year":"2021","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.waojou.2022.100737_bib62","first-page":"303","article-title":"Dupilumab-associated blepharoconjunctivitis with giant papillae","volume":"13","author":"Vingopoulos","year":"2020","journal-title":"Int Med Case Rep J"},{"key":"10.1016\/j.waojou.2022.100737_bib63","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/bjd.18031","article-title":"Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series","volume":"181","author":"Willsmore","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.waojou.2022.100737_bib64","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jdcr.2021.12.011","article-title":"Review of dupilumab-associated inflammatory arthritis: an approach to clinical analysis and management","volume":"21","author":"Jay","year":"2022","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.waojou.2022.100737_bib65","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.1111\/1346-8138.14880","article-title":"Case of alopecia areata during dupilumab treatment for atopic dermatitis","volume":"46","author":"Kanda","year":"2019","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.waojou.2022.100737_bib66","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1002\/ccr3.2871","article-title":"Seborrhoeic dermatitis and sebopsoriasis developing in patients on dupilumab: two case reports","volume":"8","author":"Al-Janabi","year":"2020","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.waojou.2022.100737_bib67","doi-asserted-by":"crossref","first-page":"106","DOI":"10.12788\/cutis.0316","article-title":"Dupilumab-Induced facial flushing after alcohol consumption","volume":"108","author":"Brownstone","year":"2021","journal-title":"Cutis"},{"key":"10.1016\/j.waojou.2022.100737_bib68","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1080\/09546634.2019.1624683","article-title":"Rosacea associated with dupilumab therapy","volume":"32","author":"Heibel","year":"2021","journal-title":"J\u00a0Dermatol Treat"},{"key":"10.1016\/j.waojou.2022.100737_bib69","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jdcr.2021.11.007","article-title":"Dupilumab-induced erythema nodosum","volume":"19","author":"Mustin","year":"2022","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.waojou.2022.100737_bib70","first-page":"e41","article-title":"Dermatitis and alopecia in a patient treated with dupilumab: a new adverse effect?","volume":"44","author":"Salguero-Fernandez","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.waojou.2022.100737_bib71","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13142","article-title":"Occurrence of\u00a0psoriasiform eruption during dupilumab therapy for adult\u00a0atopic dermatitis: a case series","volume":"32","author":"Napolitano","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.waojou.2022.100737_bib72","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/ced.14207","article-title":"Acute onset of psoriasis in a patient with atopic dermatitis treated with dupilumab","volume":"45","author":"Ferrucci","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.waojou.2022.100737_bib73","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.waojou.2022.100737_bib74","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","article-title":"Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"9","author":"Diver","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.waojou.2022.100737_bib75","series-title":"Tralokinumab [package Insert]","year":"2022"},{"key":"10.1016\/j.waojou.2022.100737_bib76","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.waojou.2022.100737_bib77","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.19573","article-title":"Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial","volume":"184","author":"Silverberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.waojou.2022.100737_bib78","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1111\/jdv.17824","article-title":"A\u00a0rare case of vernal keratoconjunctivitis in a patient with atopic dermatitis treated with tralokinumab","volume":"36","author":"Lai","year":"2022","journal-title":"J\u00a0Eur Acad Dermatol Venereol"}],"container-title":["World Allergy Organization Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939455122001132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939455122001132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:46:01Z","timestamp":1761849961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1939455122001132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1939455122001132"],"URL":"https:\/\/doi.org\/10.1016\/j.waojou.2022.100737","relation":{},"ISSN":["1939-4551"],"issn-type":[{"value":"1939-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risks and safety of biologics: A practical guide for allergists","name":"articletitle","label":"Article Title"},{"value":"World Allergy Organization Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.waojou.2022.100737","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc. on behalf of World Allergy Organization.","name":"copyright","label":"Copyright"}],"article-number":"100737"}}